AstraZeneca stock sinks on reports of merger talks with Bristol Myers Squibb

A combination of the two pharmaceutical companies could create an entity valued at nearly $400 billion, according to the Financial Times

AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of ​the world's biggest drugmakers

AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.

Astrazeneca’s share price declined sharply in early trading after investors cast doubt over the potential merger with its US rival. The UK drugmaker’s shares suffered a six per cent decline in early trading to 11,866p, after reports it was exploring a possible $400bn megadeal with Bristol Myers Squibb.  The FTSE 100 gi

The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks  WSJ

The companies have discussed a potential merger over several months, the Financial Times reported on Sunday.

A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.

AstraZeneca shares tumble 7% after reported Bristol Myers talks  Reuters

AstraZeneca shares fall on Bristol Myers Squibb merger talks  The Times

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.

Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to take over its US rival Bristol Myers Squibb in a deal that would create a near-$400bn (£300bn) pharmaceutical group.

The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.

Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.

The deal could create one of the world’s biggest pharmaceutical groups with a combined value of nearly US$400 billion.

Tie-up would create one of the world’s biggest drugmakers